Gating of auditory P50 in schizophrenics: Unique effects of clozapine

Biological Psychiatry

Volumn 40, Issue 3, 1996, Pages 181-188

  Nagamoto, Herbert T ^a,b   Adler, Lawrence E ^a   Hea, Rebecca A ^a   Griffith, Jay M ^a   McRae, Kara A ^a   Freedman, Robert ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Auditory evoked potential; clozapine; neuroleptics; schizophrenia; sensory gating

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; AUDITORY DISCRIMINATION; CHANNEL GATING; CLINICAL ARTICLE; DRUG EFFECT; DRUG RECEPTOR BINDING; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY STIMULATION;

EID: 0030574555     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00371-1     Document Type: Article

References (57)

1. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R (1982): Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating and schizophrenia. Biol Psychiatry 17:639-654.
2. Adler LE, Rose G, Freedman R (1986): Neurophysiological studies of sensory gating in rats: Effects of amphetamine, phencyclidine, and haloperidol. Biol Psychiatry 21:787-798.
3. Adler LE, Gerhardt GA, Franks R, Baker N, Nagamoto H, Drebing C, Freedman R (1990): Sensory physiology and catecholamines in schizophrenia and mania. Psychiatry Res 31:(3):297-309.
4. Adler LE, Hoffer LJ, Griffith J, Waldo M, Freedman R (1992): Normalization of nicotine by deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 32:607-616.
5. Adler LE, Hoffer LD, Wiser A, Freedman R (1993): Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150:1856-1861.
6. American Psychological Association (1987): Diagnostic and Statistical Manual of Mental Disorders (third edition, revised). Washington, D.C., American Psychological Association Press.
7. Ashby CR, Edwards E, Harkins KL, Wang RY (1989): Differential effect of typical and atypical antipsychotic drugs on the suppressant action of 2-methylserotonin on medial prefrontal cortical cells: a microiontophoretic study. Eur J Pharmacol 166:583-584.
8. Bakshi VP, Swerdlow NR, Geyer MA (1994): Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787-794.
9. Baldessarini RJ, Frankenburg FF (1991): Clozapine: A novel antipsychotic agent. N Engl J Med 324(11):746-754.
10. Barnes JM, Barnes NM, Costall B, Naylor RJ, Tyers MB (1989): 5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissues. Nature 338:762-763.
11. Boutros NN, Zouridakis G, Overall J (1991): Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 22:40-45.
12. Coppola R (1979): Isolating low frequency activity in EEG spectrum analysis. Electroencephalogr Clin Neurophysiol 46.21:101-105.
13. Costall B, Naylor RJ (1992): 5-HT receptors and antipsychotic drugs. In Marsden CA, Heal DJ (eds): Central Serotonin Receptors and Psychotropic Drugs. Oxford: Blackwell Scientific Publishers, p 214.
14. Curzon P, Kim DJB, Decker MW (1994): Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. Pharmacol Biochem Behav 49:877-882.
15. Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, Davis KL (1993): Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 46:151-163.
16. Doze VA, Cohen GA, Madison DV (1991): Synaptic localization of adrenergic disinhibition in the rat hippocampus. Neuron 6:889-900.
17. Eccles JC (1969): The Inhibitory Pathways of the Central Nervous System. Liverpool: University Press.
18. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD (1983): Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: Comparison of medicated and drug-free patients. Biol Psychiatry 18:537-551.
19. Freund TF, Gulyas AL, Acsady L, Gorcs T, Toth K (1990): Serotoninergic control of the hippocampus via local inhibitory neurons. Proc Natl Acad Sci USA 87:8501-8505.
20. Friedman L, Jesberger JA, Meltzer HY (1991): Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia. Psychiatry Res 41:25-36.
21. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz CS, Weinberger DR (1993): The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43-48.
22. Green Al, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ (1993): Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res 46:139-149.
23. Gross G, Schumann HJ (1980): Enhancement of noradrenaline release from rat cerebral cortex by neuroleptic drugs. Naunyn-Schmiedeberg's Arch Pharmacol 315:103-109.
24. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993): Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702-712.
25. Hoyer D, Gozlan H, Bolanos F, Schechter LE, Hamon M (1989): Interaction of psychotropic drugs with central 5-HT3 recognition sites: Fact or artifact? Eur J Pharmacol 171:137-139.
26. Judd LJ, McAdams L, Budnick B, Braff DL (1992): Sensory gating deficits in schizophrenia: New results. Am J Psychiatry 149:488-493.
27. Kane JM, Honigfeld G, Singer J, Meltzer HY, and the Clozaril Collaborative Study Group (1988): Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
28. Kathmann N, Engel RR (1990): Sensory gating in normal subjects and schizophrenic patients: A failure to find strong P50 suppression in normal subjects. Biol Psychiatry 27: 1216-1226.
29. Kay SR, Fiszbein A, Opler LA (1987): The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261-276.
30. Kenny JT, Meltzer HY (1991): Attention and higher cortical functions in schizophrenia. J Neuropsychiatry 3:269-275.
31. Klein C, Andresen B (1991); On the influence of smoking upon smooth pursuit eye movements of schizophrenics and normal controls. J Psychophysiology 5:361-369.
32. Krupp P, Barnes P (1989): Leponex-associated agranulocytopenia: A review of the situation. Psychopharmacology 99: S118-S121.
33. Luntz-Leybman V, Bickford PC, Freedman R (1992): Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 587:130-136.
34. Madison DV, Nicoll RA (1988): Norepinephrine decreases synaptic inhibition in the rat hippocampus. Brain Res 442: 131-138.
35. McEvoy JP, Rose JE, Levin ED, VanderZwaag C, McGee M (1994): Clozapine decreases drive to smoke. VIIth Biennial European Workshop on Schizophrenia, 1994. Schizophr Res 11(2):104.
36. McGhie A, Chapman JS (1961): Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34:103.
37. Meltzer HY (1989): Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27.
38. Meltzer HY (1992a): The mechanism of action of clozapine in relation to its clinical advantages. In Meltzer HY (ed), Novel Antipsychotic Drugs. New York: Raven Press, pp 1-13.
39. Meltzer HY (1992b): Dimensions of outcome with clozapine. Br J Psychiatry 160, S17:46-53.
40. 2 receptors in the rat brain: Neurochemical identification of cell types by immunohistochemistry. Neuropsychopharmacology 11:157-166.
41. Nagamoto HT, Adler LE, Waldo MC, Freedman R (1989): Sensory gating in schizophrenics and normal controls: Effects of changing stimulation interval. Biol Psychiatry 25:549-561.
42. Nagamoto HT, Adler LE, Waldo MC, Griffith J, Freedman R (1991): Gating of auditory response in schizophrenics and normal controls: Effects of recording site and stimulation interval on the P50 wave. Schizophr Res 4:31-40.
43. Nagamoto HT, Adler LE, Hea RA, Hoffer LD, Freedman R (1993): Gating of auditory P50 in schizophrenia: Trait and state related phenomena. Society of Biological Psychiatry Annual Meeting 1993. Biol Psychiatry 33:120A.
44. Overall JE (1988): The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 24:97-99.
45. Palreyman MG, Sorensen SM, Baron BM, Humphreys TM, Moser P, Dudley MW (1992): Antipsychotic potential of 5-HT3 antagonists: Preclinical data. In Meltzer HY (ed), Novel Antipsychotic Drugs. New York: Raven Press, pp 211-223.
46. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH (1992): Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparisons with fluphenazine. Arch Gen Psychiatry 49:345-353.
47. Schwartz M, Shagass C (1963): Reticular modification of somatosensory cortical recovery function. Electroencephalogr Clin Neurophysiol 15:265-271.
48. Seeman P (1992): Therapeutic levels of neuroleptics occupy D2 receptors, Clozapine occupies D4. Neuropsychopharmacology 7:261-284.
49. 2-activated interneuron. Brain Res 506:62-69.
50. Smith DA, Boutros NN, Schwarzkopf SB (1994): Reliability of P50 auditory event-related potential indices of sensory gating. Psychophysiology 31:495-502.
51. Straumanis JJ, Shagass C, Romer RA (1982): Influence of antipsychotic and antidepressant drugs on evoked potential correlates of psychosis. Biol Psychiatry 17:1101-1122.
52. Swerdlow NR, Geyer MA (1993): Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav 44:741-744.
53. Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991): Cloning of a human dopamine D4 receptor gene with high affinity for the antipsychotic clozapine. Nature 350:614-619.
54. Venables P (1964): Input dysfunction in schizophrenia. In Maher, BA (ed), Progress in Experimental Personality Research, Orlando, Fl: Academic Press, pp 1-47.
55. Waldo M, Gerhardt G, Baker N, Drebing C, Adler L, Freedman R (1992): Auditory sensory gating and catecholamine metabolism in schizophrenic and normal subjects. Psychiatry Res 44:21-32.
56. 3-like receptors in the actions of clozapine. J Clin Psychiatry 55:Suppl B, 123-126.
57. Wu JC, Potkin SG, Ploszaj DI, Lau V, Telford J, Richmond G (1992): Clozapine improves sensory gating more than haldol. New Research Program and Abstracts. APA Annual Meeting 1992, p. 156.